Supported by the National Eye Institute of the National Institutes of Health under Award Numbers R01EY029595 and R21EY030619, Research to Prevent Blindness, EyeSight Foundation of Alabama, and the Dorsett Davis Discovery Fund.
Data Availability: The data and code generated during the study are accessible from the corresponding author based on reasonable request and subject to the rule/regulatory of the involved institutes.
Disclosure: S. Fasih-Ahmad, None; Z. Wang, None; Z. Mishra, None; C. Vatanatham, None; M.E. Clark, None; T.A. Swain, None; C.A. Curcio, Genentech/Hoffman LaRoche (F), Heidelberg Engineering (F), Regeneron (F), and Novartis (F), Apellis (C), Astellas (C), Boehringer Ingelheim (C), Character Biosciences (C), Osanni (C), and Annexon (C) (outside this project); C. Owsley, Johnson & Johnson Vision (C) (outside this project) and AdaptDx (P); S.R. Sadda, 4DMT (C), Alexion (C), Allergan Inc. (C), Alnylam Pharmaceuticals (C), Amgen Inc. (C), Apellis Pharmaceuticals, Inc. (C), Astellas (C), Bayer (C), Healthcare Pharmaceuticals (C), Biogen MA, Inc. (C), Boehringer Ingelheim (C), Carl Zeiss Meditec (C), Catalyst Pharmaceuticals Inc. (C), Centervue Inc. (C), Genentech (C), Gyroscope Therapeutics (C), Heidelberg Engineering (C), Hoffman La Roche, Ltd. (C), Iveric Bio (C), Janssen Pharmaceuticals, Inc. (C), Merck & Co., Inc. (C), Nanoscope (C), Notal Vision Inc. (C), Novartis (C), Optos Inc. (C), Oxurion/Thrombogenics (C), Oyster Point Pharma (C), Pfizer Inc. (C), Regeneron Pharmaceuticals Inc. (C), Samsung Bioepis (C), and Vertex Pharmaceuticals Inc. (C), lectures for Carl Zeiss Meditec, Heidelberg Engineering, Nidek Inc., Novartis Pharma, and Topcon Medical Systems Inc., and Carl Zeiss Meditec (F), and Heidelberg Engineering (F) (outside this project); Z.J. Hu, Heidelberg Engineering (F) (outside this project)